Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHAT | P28329 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5816057 | 0.83 | CHRM5 (0.44) | CHRM5CYP1A2CYP2C9CHATMAOB | |
| SCHEMBL8310443 | 0.83 | NFE2L2 (0.48) | CHRM5CYP1A2CYP3A4CYP2D6KMT2A | |
| SCHEMBL8397406 | 0.80 | TAAR1 (0.45) | ALDH1A1L3MBTL1KMT2AMEN1LMNA | |
| SCHEMBL27787151 | 0.75 | GRIN2B (0.48) | CHRM5CYP1A2CYP2C9ALDH1A1HPGD | |
| SCHEMBL6031658 | 0.73 | CHRM5 (0.53) | CHRM5CYP1A2CYP2C9CYP3A4TAAR1 | |
| SCHEMBL23457217 | 0.72 | CHRM5 (0.52) | CHRM5CYP1A2CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL3937409 | 0.72 | CHRM5 (0.47) | CHRM5CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL19423487 | 0.71 | NFE2L2 (0.43) | CYP1A2ALDH1A1KMT2AMAPTNPC1 | |
| SCHEMBL1133197 | 0.70 | ALDH1A1 (0.41) | CYP1A2CYP2C9ALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL1989041 | 0.70 | CHRM5 (0.54) | CHRM5CYP1A2CYP2C9ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777077-B2 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE, INC. (US) | 2010-08-17 | — | — | US | claimed |
| EP-2132187-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| WO-2008097459-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | claimed |
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8735625-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8394846-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8143298-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7777077-B2 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2132187-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008097459-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CHRM5 270/4885CYP1A2 1422/4885CYP2C9 1248/4885 |
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CHRM5 270/4885CYP1A2 1422/4885CYP2C9 1248/4885 |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CHRM5 270/4885CYP1A2 1422/4885CYP2C9 1248/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | CHRM5 81/4885CYP1A2 1610/4885CYP2C9 987/4885 |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CHRM5 270/4885CYP1A2 1422/4885CYP2C9 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.